The COVID-19 pandemic has resulted in a devastating plunge in the number of cancer screenings in the U.S. during the past year.
A new report anticipates a 30 percent rise in newly diagnosed cases of prostate cancer in 2021, due in part to men deferring their annual checkups because of the pandemic. This means that nearly 250,000 men will be diagnosed with prostate cancer in 2021, and more than 34,100 men will die as a result. Leading physicians and researchers say 2022 numbers could be even higher.
The report also found that the incidence of prostate cancer is almost 80 percent higher in non-Hispanic Black men than in non-Hispanic white men, and the death rate for Black men with prostate cancer is more than double that of men in every other group. There are multiple reasons for this disparity. Since prostate cancer is slow to develop, if it is caught early and actively monitored, men are more likely to have positive outcomes.
This education activity will provide guidance on the optimal management of mCSPC to oncologists, urologists, oncology advanced practitioners and other members of the multidisciplinary cancer care team. The educational program will address some of the challenges in optimal sequencing of care in mCSPC and will provide an opportunity to discuss with leading oncology experts and colleagues how new research clinical updates can be translated into new patient care strategies.
Learn More & Register
This new project will join other ACCC initiatives that are addressing inequities in cancer care, including increasing the representation of minorities in cancer clinical trials and eliminating disparities in access to precision medicine.
Through a partnership with the American Cancer Society and Project ECHO, ACCC is offering the latest content knowledge and best practices related to bone health in patients with breast cancer and patients with prostate cancer. Participation in the ECHO Clinic is free. Sessions are held monthly by videoconference.
View Topics & Schedule